TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential. On January 27, TD Cowen analyst Ritu Baral maintained the firm’s Hold rating on Amicus Therapeutics Inc. (NASDAQ:FOLD), as well as the $14.50 price target on the stock. Amicus’s pre-announced fourth-quarter and full-year 2025 total product revenue were modestly above expectations, according to TD Cowen, with Fabry disease medication Galafold delivering a clear outperformance versus consensus estimates, while revenues from Pompe disease medications came in roughly in line with broader Wall Street expectations.
TD Cowen also noted that the strategic landscape for the Amicus Therapeutics Inc. (NASDAQ:FOLD) stock is now largely defined by BioMarin’s agreement to acquire Amicus for $14.50 per share in cash, with the deal already approved by both companies’ boards and expected to close by the second quarter of 2026, subject to shareholder and regulatory approvals. With a fixed takeout price and a clear M&A timeline, the scope for further meaningful appreciation in Amicus Therapeutics Inc. (NASDAQ:FOLD) share price is constrained primarily to potential deal-spread dynamics and low-probability transaction risk, rather than fundamentals-driven multiple expansion, according to the analyst.
Amicus Therapeutics Inc. (NASDAQ:FOLD) is a biotechnology company that focuses on discovering, developing, and delivering medicines for people living with metabolic diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Will the Fed "continue raising interest rates"? Will the "tightening cycle" of the late 1980s be repeated?
The Citi report points out that the current macro environment is highly similar to the tightening cycle of 1988-1989, when the economy remained resilient and inflation pressures gradually accumulated, followed by a slowdown in economic activity before policies shifted to easing. During that tightening cycle, the Federal Reserve raised interest rates 16 times in a row.
Rare alliance of arch-rivals! Musk and Altman support Dario Amodei's call to "slow down AI globally"
Anthropic's Amodei issued a call to "slow down AI globally," and to everyone's surprise, rivals Musk and Altman both publicly endorsed the initiative. The three industry giants unanimously agreed to grant third-party access to "employee-level" evaluation rights and to implement coordinated deceleration measures. Altman went further, announcing that OpenAI will not IPO this year. The resignation of a researcher and a collective breakout of uncontrollable AI systems have ignited long-standing industry fears.
Bitcoin vs Ethereum ETFs: Which asset is winning September’s flow battle?
Solana targets $147 as it breaks key resistance and eyes further gains
Crypto prices
More
